beta

LGVN

Longeveron Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

longeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. our allogeneic, ‘off-the-shelf’ product is under investigation for chronic conditions of the elderly, and other life- threatening diseases, for which no approved therapeutics currently exist: • aging frailty syndrome • alzheimer’s disease • hypoplastic left heart syndrome • the metabolic syndrome

Market Cap: 5.46 Million

Primary Exchange: NASDAQ

Website: longeveron.com

Shares Outstanding: 10.3 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.21959709674339134

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 712 trading days

From: 2021-11-24 To: 2024-03-07

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud